Bristol Myers Squibb is a global biopharmaceutical company committed to discovering, developing and delivering innovative medicines to patients with serious diseases.

The Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb (BMS), is an American multinational pharmaceutical company. Headquartered in Princeton, New Jersey, [2] BMS is one of the world's largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations.

Learn about global biopharmaceutical innovator Bristol Myers Squibb, helping millions to fight cancer, cardiovascular disease, HIV/AIDS, and more.

Discover what it means to have a meaningful career. At Bristol Myers Squibb, you'll transform patients' lives and help them prevail over serious diseases.

To be the world’s leading biopharma company that transforms patients’ lives through science. We demonstrate ethics, integrity and quality in everything we do for patients, customers and colleagues. We move together with speed and quality because patients are waiting.

2025年2月6日 · Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

6 天之前 · Bristol Myers Squibb (BMS) says it is applying artificial intelligence (AI) and machine learning, combining those with its researchers’ expertise in drug targets and mechanisms of action, to ...

2024年10月29日 · Bristol-Myers Squibb (BMS) is a company engaged in the discovery, development, licensing, manufacturing, marketing, and distribution of biopharmaceutical products.

We are committed to discovering, developing and delivering transformational medicines in disease areas where we believe we can make a meaningful difference — and we made strong …

2025年3月11日 · Bristol Myers Squibb (BMS) has agreed to acquire its longtime cell therapy partner 2seventy bio in a deal valued at $286m. ... GlobalData is the parent company of Pharmaceutical Technology. In September 2024, the two companies announced plans to discontinue enrolment of subjects in the Phase III KarMMa-9 clinical trial (NCT06045806) of …